HIGHLIGHTS
- What: The authors evaluated the therapeutic potential of donepezil, a reversible acetylcholinesterase inhibitor approved by the FDA (Bryson and Benfield, 1997), in four children affected by GoF variants of KCNQ2 and KCNQ3 encephalopathy.
- Who: Andreea Nissenkorn from the University of Naples Federico II, Italy have published the research work: Donepezil as a new therapeutic potential in KCNQ2- and KCNQ3-related autism, in the Journal: (JOURNAL) of 01/02/2024
- How: After the 12-month evaluation the results were discussed with the caregivers and they opted accordingly to continue or withdraw from the study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.